Veritas In Silico Inc. (TYO:130A)
Japan · Delayed Price · Currency is JPY 487.00
+12.00 (2.53%)
Last updated: Feb 16, 2026, 3:09 PM JST
Veritas In Silico Company Description
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA.
The company has strategic partnership with Liverpool ChiroChem for the mRNA-targeted drug discovery and development.
Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan.
Veritas In Silico Inc.
| Country | Japan |
| Founded | 2016 |
| Industry | Surgical and Medical Instruments and Apparatus |
| CEO | Shingo Nakamura |
Contact Details
Address: 1-11-1 Nishigotanda Shinagawa, 141-0031 Japan | |
| Phone | 81 3 6421 7537 |
| Website | veritasinsilico.com |
Stock Details
| Ticker Symbol | 130A |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Shingo Nakamura | Chief Executive Officer |
| Hiroyuki Matsuoka | Chief Financial Officer |
| Takashi Kamimura | Chief Operating Officer |